What this is
- How it works
- How it works isn't classified yet
- Tested for
- HIV, HIV Infection
- Main trialPhase 2
- “The study will begin with a two-week lead-in period (W-2 and W-1), when participants randomized to Codivir® will receive Codivir® 2 mL, 1 subcutaneous injection every day. Participants randomized to Standard Antiretroviral Treatment will wait for the next step. At V0 (W0, D0) all participants will start the antiretroviral treatment described above. From V0 (W0, D0) to V6 (W12, D84) participants randomized to Codivir® will receive Codivir® as complementary therapy to the above antiretrovirals on alternate days (every other day). At V6 (W12, D84) treatment with Codivir® will end. At V7 (W24,…”In the company’s words, NCT06676410 on ClinicalTrials.gov
Other drugs for HIV
- ACC017Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Phase 3
- AlimatravirMerck & Co. · Phase 3
- IslatravirMerck & Co. · Phase 2/3
- UlonivirineMerck & Co. · Phase 2/3
- ISL/ULOMerck & Co. · Phase 2/3
- CabotegravirViiV Healthcare · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2024 | Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026